SUBSCRIBE
SUBSCRIBE

Scioderm

NEWS
Scioderm was acquired by Amicus Therapeutics in September 2015.
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Amicus Snaps up Scioderm and its Lead EB Drug in Deal Worth $847 Million
August 31, 2015
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Bio NC
Scioderm Locks In $20 Million Series B
December 18, 2014
 · 
2 min read
IN THE PRESS
Deals
Amicus Completes Acquisition Of Scioderm
September 30, 2015
 · 
9 min read
Policy
Scioderm To Submit Rolling NDA To U.S. FDA For Zorblisa
July 14, 2015
 · 
4 min read
Drug Development
Scioderm Initiates Phase 3 Registration Trial Of Zorblisatm (SD-101), A Novel Topical Therapy For Patients With Epidermolysis Bullosa
March 19, 2015
 · 
3 min read
Business
Scioderm Appoints Ian A. W. Howes Chief Financial Officer
January 6, 2015
 · 
4 min read
Bio NC
Scioderm To Present At 33rd Annual J.P. Morgan Healthcare Conference
January 2, 2015
 · 
3 min read
Drug Development
Scioderm, Inc. To Present Data From Phase 2b Study Of Zorblisa™ (SD-101) At The 13th Annual Scioderm Investor Forum
October 6, 2014
 · 
2 min read
Drug Development
Scioderm To Present Data From Phase 2b Study Of Zorblisa™ (SD-101) At The Debra International Congress
September 9, 2014
 · 
2 min read
Business
Scioderm Names Ronald Nardi, Ph.D. Chief Scientific Officer
June 12, 2014
 · 
3 min read
Drug Development
Scioderm Receives Orphan Drug Designation In The European Union For Novel Topical Therapy To Treat Epidermolysis Bullosa
January 23, 2014
 · 
3 min read
BioCapital
Scioderm To Present At 32nd Annual J.P. Morgan Healthcare Conference
January 7, 2014
 · 
2 min read
Load More
AWARDS
  • NextGen Class of 2015